BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carb-X
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200924T093000
DTEND;TZID=America/New_York:20200924T113000
DTSTAMP:20260403T183359
CREATED:20200908T154818Z
LAST-MODIFIED:20200908T154944Z
UID:4319-1600939800-1600947000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Moving from preclinical to clinical-stage: Challenges and opportunities
DESCRIPTION:Speakers: \n\nValue of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience – Bala Subramanian\, Bugworks Research Inc.\nAmicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections – Michael P. Bevilacqua\, Amicrobe\, Inc.\nDiscovery and development of microbiome therapeutics using reverse translation – Matthew Henn & Chris Ford\, Seres\nTherapeutics Development of a multi-component toxoid vaccine for S. aureus – Regulatory challenges and opportunities – M. Javad Aman & Catherine Bernard\, Integrated BioTherapeutics\nRegulatory challenges for RaPID/BSI – culture-free identification and characterization of bloodstream infections – David Steinmiller\, HelixBind Inc.\n\nModerator: Erin Duffy\, CARB-X \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200924T090000
DTEND;TZID=America/New_York:20200924T100000
DTSTAMP:20260403T183359
CREATED:20200916T174543Z
LAST-MODIFIED:20200916T174543Z
UID:4344-1600938000-1600941600@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: The global movement of microorganisms: Tracking the spread of difficult-to-treat infections
DESCRIPTION:AMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nTracking the spread of COVID-19 has been critical to the global public health response. This information allows hospitals to prepare for surges\, governments to deploy testing strategies\, and citizens to modify their behavior appropriately. But while information about COVID-19 is readily and publicly available\, the world still struggles to monitor and track the spread of drug resistant infections.How should global monitoring and data sharing evolve to combat antimicrobial resistance? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-the-global-movement-of-microorganisms-tracking-the-spread-of-difficult-to-treat-infections/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200923
DTEND;VALUE=DATE:20200926
DTSTAMP:20260403T183359
CREATED:20200820T183607Z
LAST-MODIFIED:20200820T183720Z
UID:4292-1600819200-1601078399@carb-x.org
SUMMARY:ESCMID Conference on Coronavirus Disease (ECCVID)
DESCRIPTION:Speakers include Kevin Outterson\, Executive Director of CARB-X. \nThe ESCMID Conference on Coronavirus Disease (ECCVID) will take place online from Wednesday 23rd to Friday 25th September 2020 and will cover all aspects of COVID-19. ECCVID will feature a comprehensive scientific programme that will span a wide range of topics surrounding this emerging threat.  \nCOVID-19 is a major public health incident which has brought about significant challenges and uncertainties with respect to diagnostics\, therapeutics and infection prevention and control. We are learning continually about the new SARS-CoV-2 virus and an international scientific event that brings together the latest research and scientific evidence is very timely. ECCVID will offer excellent opportunities to showcase the latest findings\, share experiences and knowledge and demonstrate practical techniques and guidance.  \nInternationally renowned clinical microbiologists\, infectious diseases specialists and experts from related disciplines will present their work and latest findings on COVID-19\, during the event. \nClick here to learn more.\nClick here to view the programme.\nClick here to register. \n 
URL:https://carb-x.org/event/escmid-conference-on-coronavirus-disease-eccvid/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200922T070000
DTEND;TZID=America/New_York:20200922T080000
DTSTAMP:20260403T183359
CREATED:20200908T153527Z
LAST-MODIFIED:20200908T153553Z
UID:4314-1600758000-1600761600@carb-x.org
SUMMARY:Chatham House Webinar: Creating a New Generation of Antibiotics
DESCRIPTION:Participants include Kevin Outterson\, Executive Director of CARB-X. \nThe world needs a new generation of antibiotics to address the rapid growth in antibiotic-resistant bacteria. The UK government’s 2014 Review on Antimicrobial Resistance estimated that such bacteria could result in the deaths of 10 million people a year by 2050 and an accumulated cost of up to $100 trillion to the global economy. Despite this urgent need\, there remain few new antibiotics in development due to a lack of commercial viability for pharmaceutical companies with a 2019 Chatham House report highlighting the lack of progress being made on critical recommendations to tackle antimicrobial resistance. \nThis event will discuss the urgency of the development of new antibiotics and recent efforts to address the funding gap. What is the significance of the rise of antibiotic-resistant bacteria? What are the challenges at the intersection of increasing demand for new antibiotics and their commercial viability? Does the recent announcement of a new fund from the pharmaceutical industry represent a major shift\, or just the beginning\, of what is needed? \nParticipants: \n\nThomas Cueni\, Director General\, IFPMA\nJim O’Neill\, Chair\, Chatham House\nKevin Outterson\, Associate Fellow\, Global Health Programme\, Chatham House\nLaura Piddock\, Professor of Microbiology; Deputy Director of the\nInstitute of Microbiology and Infection\, University of Birmingham\nChair: Emma Ross\, Senior Research Fellow\, Global Health Programme\, Chatham House\n\nTo learn more\, click here.
URL:https://carb-x.org/event/chatham-house-webinar-webinar-creating-a-new-generation-of-antibiotics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200919T090000
DTEND;TZID=America/New_York:20200919T100000
DTSTAMP:20260403T183359
CREATED:20200916T174934Z
LAST-MODIFIED:20200916T174934Z
UID:4347-1600506000-1600509600@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: Responding to difficult-to-treat infections: Role and responsibilities of governments\, researchers\, clinicians\, industry and patients
DESCRIPTION:AMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nGovernments\, researchers\, and industry partners around the world have mobilized to develop diagnostics\, therapeutics\, and vaccines for COVID-19. The development of new recommendations and practices continue to be deployed to slow the spread of COVID-19. The burden of drug-resistant infections could surpass COVID-19. Drugs like antibiotics are a vital tool for modern medicine\, used to prevent and treat infections. As drug-resistant infections are becoming more common\, modern medicine as we know it is at risk and much like COVID-19\, it has the potential to overwhelm our healthcare structure. What changes are needed to reshape strategies for combatting antimicrobial resistance globally? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-responding-to-difficult-to-treat-infections-role-and-responsibilities-of-governments-researchers-clinicians-industry-and-patients/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200917T140000
DTEND;TZID=America/New_York:20200917T153000
DTSTAMP:20260403T183359
CREATED:20200916T133131Z
LAST-MODIFIED:20200916T133131Z
UID:4337-1600351200-1600356600@carb-x.org
SUMMARY:Building\, Funding\, and Growing Successful Biotech Startups
DESCRIPTION:Speakers include Cameron Bess\, Project Officer\, Antibacterials Branch\, Division of CBRN Medical Countermeasures\, BARDA. \nTurning a good scientific idea into a successful biotech startup is a challenging journey.This panel will highlight several successful paths that scientists can take toward creating a successful biotech company. Learn what New York-area resources are available to turn your idea into a business and help you develop entrepreneurial skills. \nThe event will introduce funding and strategic programs available from IndieBio\, the Center for Biotechnology\, the National Institutes of Health (NIH)\, and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). \nSpeakers include: \n\nAnton Xavier\, Assistant Director of Technology and Business Development at the Center for Biotechnology.\nPhuong Nguyen\, Commercialization Fellow at the Center for Biotechnology.\nStephen Chambers\, Managing Director of IndieBio in New York.\nMatthew McMahon\, Director of NIH’s Small Business Education and Entrepreneurial Development (SEED) Program.\nCameron Bess\, Project Officer\, Antibacterials Branch\, Division of CBRN Medical Countermeasures\, BARDA.\n\nTo learn more and register\, click here. 
URL:https://carb-x.org/event/building-funding-and-growing-successful-biotech-startups/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200909
DTEND;VALUE=DATE:20200911
DTSTAMP:20260403T183359
CREATED:20200819T141833Z
LAST-MODIFIED:20200820T183034Z
UID:4281-1599609600-1599782399@carb-x.org
SUMMARY:PACCARB: Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
DESCRIPTION:The September PACCARB meeting\, held virtually\, will focus on welcoming eight new liaison members and on the impact of COVID-19 and its affect on antimicrobial resistance (AMR). Topics will include presentations on the COVID-19 mortality rate due to secondary acquired infections\, antibiotic stewardship practices during a pandemic\, disruptions in the agricultural industry due to COVID-19 and the intersection of AMR and emergency preparedness. \nThis virtual public meeting is hosted by HHS and is open to the public. It will be held via webcast.The meeting can be accessed through a live webcast on the day of the meeting. \nLive Webcast: www.hhs.gov/live\nClick here to learn more.
URL:https://carb-x.org/event/paccarb-presidential-advisory-council-on-combating-antibiotic-resistant-bacteria/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200827T060000
DTEND;TZID=America/New_York:20200827T070000
DTSTAMP:20260403T183359
CREATED:20200817T132156Z
LAST-MODIFIED:20200824T153824Z
UID:4255-1598508000-1598511600@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: SME campus (Part II) | Focus on diagnostics
DESCRIPTION:Moderator: \n\nBetsy Wonderly Trainor\, Alliance Director\, CARB-X\n\nSpeakers: \n\nPeter Haug – CFO & Co-Founder\, Head of Business Development & Licensing\, Noscendo GmbH\nPiotr Gastrecki – CTO\, ScopeFluidics\nRosemarie Preyer – GenID GmbH
URL:https://carb-x.org/event/biocom-4th-amr-conference-sme-campus-part-ii-focus-on-diagnostics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200827
DTEND;VALUE=DATE:20200829
DTSTAMP:20260403T183359
CREATED:20200819T141417Z
LAST-MODIFIED:20200824T153935Z
UID:4279-1598486400-1598659199@carb-x.org
SUMMARY:Bacteriophage Therapy Summit
DESCRIPTION:As the scientific community search for alternatives to broad spectrum antibiotics\, phage therapy has re-emerged as a viable solution to tackle the global health challenge of anti-microbial resistance. \nAs such\, the 2nd Bacteriophage Therapy Summit returns digitally as a dedicated platform for leaders in industry and academia to accelerate the discovery and translation of bacteriophage research into targeted therapeutics that demonstrate clinically significant results. \nWith a heavy translationally focused agenda including how to overcome bacterial resistance scaling-up manufacturing and showing clinical efficacy this is your opportunity to join your peers to strengthen your product development pipelines and forge collaborations to unlock the full potential of bacteriophage therapeutics. \nView the full event guide for further details on speakers\, content and how to join those who paving the way for bacteriophage-based therapeutics!
URL:https://carb-x.org/event/bacteriophage-therapy-summit-2/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200825T103000
DTEND;TZID=America/New_York:20200825T114500
DTSTAMP:20260403T183359
CREATED:20200817T132110Z
LAST-MODIFIED:20200819T143706Z
UID:4254-1598351400-1598355900@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: AMR pull incentives | Will COVID-19 speed up or slow down implementation?
DESCRIPTION:Moderator:  \n\nKathy Talkington\, Director Health Programs\, Pew Charitable Trust\n\nSpeakers: \n\nColm Leonard – Clinical Advisor/Consultant\, NICE\nKevin Outterson – Professor of Law & Executive Director\, CARB-X\nElmar Nimmesgern – Secretariat Lead\, Global AMR R&D Hub\nDaniel Berman – Lead of the Global Health Team\, Longitude Prize / Nesta
URL:https://carb-x.org/event/biocom-4th-amr-conference-amr-pull-incentives-will-covid-19-speed-up-or-slow-down-implementation/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200825T091500
DTEND;TZID=America/New_York:20200825T101500
DTSTAMP:20260403T183359
CREATED:20200817T131812Z
LAST-MODIFIED:20200819T143409Z
UID:4250-1598346900-1598350500@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: Business models in AMR | How to develop strategic decisions in a challenging and global AMR market
DESCRIPTION:Moderator:  \n\nGökhan Batur – CEO\, Polyphor Ltd\n\nSpeakers: \n\nPeter Beyer – Senior Advisor Department of Essential Medicines & Health Products\, WHO\nErin Duffy – Chief of Research & Development\, CARB-X\nHolger Zimmermann – CEO\, AiCuris
URL:https://carb-x.org/event/biocom-4th-amr-conference-sme-approach-how-to-develop-strategic-decisions-in-a-challenging-and-global-amr-market/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200825T073000
DTEND;TZID=America/New_York:20200825T090000
DTSTAMP:20260403T183359
CREATED:20200817T131922Z
LAST-MODIFIED:20200819T143135Z
UID:4251-1598340600-1598346000@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: Business models | The AMR company of the future – Which route to success
DESCRIPTION:Moderator: \n\nErin Duffy – Chief of Research & Development\, CARB-X\n\nSpeakers: \n\nJonathan Butcher – Head of Business Development\, BioVersys AG\nCherif Bousselham – Senior Vice President\, Head of Sales\, EMEA\, Accelerate Diagnostics Inc.\nJean-Pierre Paccaud – Director of Business Development and Corporate Strategy\, GARDP\nKenneth Bradley – Global Head\, Infectious Disease Discovery\, Roche
URL:https://carb-x.org/event/biocom-4th-amr-conference-business-models-the-amr-company-of-the-future-which-route-to-success/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200824
DTEND;VALUE=DATE:20200829
DTSTAMP:20260403T183359
CREATED:20200214T152647Z
LAST-MODIFIED:20200824T153930Z
UID:3796-1598227200-1598659199@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics
DESCRIPTION:This year’s digital AMR Conference will be an international forum to discuss AMR in the context of COVID-19 and beyond. \nCARB-X speakers include Kevin Outterson\, Executive Director\, Erin Duffy\, Chief of Research and Development\, and Betsy Wonderly Trainor\, Alliance Director. \nThe current global health crisis caused by COVID-19 shows more than ever the importance of infectious diseases expertise and the high need for further fighting against antimicrobial resistance (AMR). A cross-sectoral international dialogue with all stakeholders involved will be crucial to help implement innovative therapies and diagnostics in the clinical practice globally. \nTogether with our supporters – among others our major partner\, the BEAM Alliance – the AMR Conference will continue to provide a (virtual) platform for those debates bringing together stakeholders from industry\, SMEs\, start-ups\, academia\, clinics\, investors\, public institutions and policy. Within our digital AMR Conference Week in August\, we want to catch up discussing the challenges of bringing new antimicrobial treatments and diagnostics into the market and as a result\, help to establish a post-COVID policy roadmap on AMR. \nFive days of insights and networking for the global AMR community: Each conference day will cover a focus topic with selected LIVE sessions and high-level panels. Additionally\, you will be able to explore scientific poster presentations and participate in virtual 1:1 meetings throughout the whole week and to engage within our new digital AMR stakeholder platform which is currently being set up. \n\n\n\n\n\nClick here to view the programme.\nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/biocom-4th-amr-conference-novel-antimicrobials-and-amr-diagnostics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200807T100000
DTEND;TZID=America/New_York:20200807T150000
DTSTAMP:20260403T183359
CREATED:20200720T163544Z
LAST-MODIFIED:20200720T163544Z
UID:4158-1596794400-1596812400@carb-x.org
SUMMARY:Longitude Prize Sprint Workshop 1 - Navigating MedTech Regulation Pathways in Developed and Emerging Markets
DESCRIPTION:In July 2020\, the Longitude Prize is launching the Longitude Prize Sprint Programme. The Sprint programme is free and will consist of a mix of Sprint Workshops and Sprint 1:1 Expert Support and is perfect for people and teams working in the field of AMR diagnostic test development. The Longitude Prize will be running three Sprint Workshop webinars from July to November 2020. The Sprint Workshops (virtual webinars) are open to all Longitude Prize Competitors\, along with diagnostic test developers who are looking for technical advice and support for regulatory pathways\, finance and investment\, and manufacture and distribution strategies.\n\n\nLongitude Prize Sprint Workshop 1 – Navigating MedTech Regulation Pathways in Developed and Emerging Markets \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMedtech product development and commercialisation for devices and diagnostics is a complex process and has a long gestation period. There are many uncertainties that Medtech product development has to navigate especially during technology development and validation stages of product development as well as being able to meet regulatory standards. Successful navigation of the regulatory maze is important in product development roadmap. \nThere are subtle and distinct variations in regulatory standards for Medtech products across different geographies especially between developed and developing countries. Another layer of complexity is the continuous change in regulatory landscapes both in mature and evolving markets across the world. \nThe workshop (virtual webinar)\, as part of the Longitude Prize Sprint programme\, will draw upon insights from experts in Medtech regulation and address the nuances of regulation in different geographies which will guide Medtech companies in their product development strategies. \n\nTo learn more\, click here. 
URL:https://carb-x.org/event/longitude-prize-sprint-workshop-1-navigating-medtech-regulation-pathways-in-developed-and-emerging-markets/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200709T030000
DTEND;TZID=America/New_York:20200709T043000
DTSTAMP:20260403T183359
CREATED:20200330T142214Z
LAST-MODIFIED:20200422T140818Z
UID:3939-1594263600-1594269000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
DESCRIPTION:Speakers: \n\nAnand Anandkumar\, Co-founder and CEO Bugworks Research Inc (India)\nKamini Walia\, Program Officer\, ICMR-AMR Initiative (India) \n\nModerator: François Franceschi\, GARDP  \nIn this webinar\, Anand Anandkumar and Kamini Walia will discuss: \n\nWhy is India one of the hotbeds of the AMR problem? Latest statistics of growing drug resistance etc.\nInitiatives of the Indian Government to curb the AMR problem\nAntimicrobial R&D landscape in India – a vibrant ecosystem supporting innovation in AMR diagnosis\, prevention and therapeutics\nFledgling antimicrobial clinical trial networks – could trials out of India play a significant role in gaining global regulatory approvals?\nChanging regulatory environment to enable accelerated approvals for antimicrobial products\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 5 May 2020\, 9:00-10:30 am CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-the-challenges-and-opportunities-for-antimicrobial-rd-in-low-and-middle-income-countries-india-case-study/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200630T110000
DTEND;TZID=America/New_York:20200630T123000
DTSTAMP:20260403T183359
CREATED:20200406T155840Z
LAST-MODIFIED:20200422T140757Z
UID:3950-1593514800-1593520200@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Clinical development of antimicrobials – Phase 1 development challenges
DESCRIPTION:Speaker: Markus Zeitlinger\, Head of Department of Clinical Pharmacology\, Medical University of Vienna (Austria) \nModerator: Markus Heep \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 30 June\, 17:00-18:30 CEST. Find your time zone here.
URL:https://carb-x.org/event/live-webinar-gardp-revive-clinical-development-of-antimicrobials-phase-1-development-challenges/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200625T110000
DTEND;TZID=America/New_York:20200625T121500
DTSTAMP:20260403T183359
CREATED:20200601T144452Z
LAST-MODIFIED:20200601T144452Z
UID:4059-1593082800-1593087300@carb-x.org
SUMMARY:JLABS Webinar: Raising Capital: A Legal Primer
DESCRIPTION:Having a clear strategy for raising growth capital and understanding the evolution and dynamic of investment deals are essential for the long-term health of your business. Join JLABS\, Allen & Overy and O’Melveny to learn more and discuss key issues such as: \n\nKey points in growth capital deals\nEvolution of deal dynamics\nBoard seats\nGovernance structure\nEconomic terms\nExit terms\n\nTo learn more\, click here.\n\nThis program is part of the Johnson & Johnson Innovation – JLABS Legal Webinar Series for life science entrepreneurs\, together with Allen & Overy and O’Melveny. You can register for other webinars in the series by visiting this page.
URL:https://carb-x.org/event/jlabs-webinar-raising-capital-a-legal-primer/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200609T120000
DTEND;TZID=America/New_York:20200609T130000
DTSTAMP:20260403T183359
CREATED:20200601T144305Z
LAST-MODIFIED:20200601T144305Z
UID:4058-1591704000-1591707600@carb-x.org
SUMMARY:JLABS Webinar: Pulse Check-Today's Funding Landscape
DESCRIPTION:Today’s current crisis has changed the mindset of many industry strategic partners\, investors and overall stakeholders. From pivoting investment priorities\, to identifying new areas of innovation\, the investor landscape is constantly shifting. \nFor small to medium sized biotechs\, it can be hard to keep up with promised milestones while also planning and anticipating the future of their companies. How could companies be preparing for not only the short-term but for years to come? What should be prioritized in the coming months? Who is still investing? How can they find the right partners for them as they move forward? \nJoin JLABS as we welcome members of Johnson and Johnson Development Corp.\, and other industry investors to: \n\n\n\n\n\n\n\n\n\nShare how they are planning for the future and pivoting in the current crisis\nWhat they believe companies should be prioritizing\nHow bio-techs could stay connected with their current and potential stakeholders\nWhere they could find the right resources and investment opportunities\, and overall gain a pulse check on the investor community\n\nTo learn more\, click here.
URL:https://carb-x.org/event/jlabs-webinar-pulse-check-todays-funding-landscape/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200609T110000
DTEND;TZID=America/New_York:20200609T123000
DTSTAMP:20260403T183359
CREATED:20200330T142524Z
LAST-MODIFIED:20200422T140732Z
UID:3943-1591700400-1591705800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
DESCRIPTION:Speaker: Vincent H. Tam\, Professor\, University of Houston College of Pharmacy (USA) \nModerator: Shampa Das\, Senior Lecturer\, Centre of Excellence in Infectious Diseases Research\, University of Liverpool (UK)  \nIn this webinar\, Vincent H. Tam will present on his work looking at studying PK/PD in fixed dose beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations. \nTopics discussed will include: \n\nUnderstanding the inherent challenges associated with PK/PD of BL/BLI combinations\nDemonstrating new approaches to gain useful insights from preclinical PK/PD models\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 9 June 2020\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-test-tube-to-patient-pk-pd-of-fixed-dose-beta-lactam-beta-lactamase-inhibitor-combinations/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200529T100000
DTEND;TZID=America/New_York:20200529T113000
DTSTAMP:20260403T183359
CREATED:20200527T163340Z
LAST-MODIFIED:20200527T163340Z
UID:4052-1590746400-1590751800@carb-x.org
SUMMARY:Live Webinar: o2h ventures 6th ChaiTime Webinar Registration
DESCRIPTION:Join us on Friday\, May 29 @ 3:00 PM BST (10:00 AM EST / 7.30 PM IST) for our the sixth o2h ventures ChaiTime webinar on ‘Antibiotic Resistance – The fight for humanity’. \nErin Duffy\, Chief of R&D\, CARB-X \, will chair the 6th o2h ventures ChaiTime discussion on drug resistance and lessons to be learned fron the COVID-19 pandemic. \nClick Here to Register for the Webinar. \nWebinar Chair: \nErin Duffy\, Chief of R&D @ CARB-X \nPanelists and Speakers: \nKen Bradley\, Global Head\, Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED) \nAnkit Mahadevia\, CEO of NASDAQ listed\, Spero Therapeutics \nPaul Finn\, CEO of Oxford University Spinout\, Oxford Drug Design \nAjay Mistry\, CEO of AI and antibiotics discovery start-up\, Oppilotech
URL:https://carb-x.org/event/live-webinar-o2h-ventures-6th-chaitime-webinar-registration/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200528T120000
DTEND;TZID=America/New_York:20200528T130000
DTSTAMP:20260403T183359
CREATED:20200504T145415Z
LAST-MODIFIED:20200504T145415Z
UID:3997-1590667200-1590670800@carb-x.org
SUMMARY:Live Webinar – CARB-X - How to Prepare for an FDA Pre-IND Meeting: Planning for Success
DESCRIPTION:Speakers: \nCarmella Moody\, Regulatory Program Director\, RTI International \nMichael Bevilacqua\, M.D.\, Ph.D.\, Chief Executive Officer and Chief Science Officer\, Amicrobe Inc. \nIn this webinar\, Carmella Moody and Michael Bevilacqua will help product developers understand how best to prepare for pre-IND meetings to ensure maximum results. \nCarmella Moody has many years experience supporting and preparing companies for pre-IND meetings. Michael Bevilacqua\, who worked with CARB-X to prepare for his company’s recent pre-IND meeting\, will discuss his positive experience and lessons learned.  Everyone is welcome to join. A recording of the webinar will be available for those who cannot attend the live broadcast. \nPresentations will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on May 28\, 12:00 to 13:00 ET (find your time zone here).
URL:https://carb-x.org/event/live-webinar-carb-x-how-to-prepare-for-an-fda-pre-ind-meeting-planning-for-success/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200519T110000
DTEND;TZID=America/New_York:20200519T123000
DTSTAMP:20260403T183359
CREATED:20200422T141057Z
LAST-MODIFIED:20200422T141057Z
UID:3982-1589886000-1589891400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Assay development for measuring antibiotic accumulation in Gram-negative bacteria
DESCRIPTION:Speakers: \n\nJessica Blair\, Institute of Microbiology and Infection\, University of Birmingham (UK)\nMark Brönstrup\, Department of Chemical Biology\, Helmholtz Centre for Infection Research (Germany)\nDavid A. Six\, Venatorx Pharmaceuticals\, Inc. (US)\n\nModerator: Alice Erwin\, Erwin Consulting LLC (US) \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-assay-development-for-measuring-antibiotic-accumulation-in-gram-negative-bacteria/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200512T110000
DTEND;TZID=America/New_York:20200512T123000
DTSTAMP:20260403T183359
CREATED:20200330T142407Z
LAST-MODIFIED:20200422T140709Z
UID:3941-1589281200-1589286600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Probability of target attainment analyses for dose selection in antimicrobial drug development
DESCRIPTION:Speaker: Shampa Das\, Senior Lecturer\, Centre of Excellence in Infectious Diseases Research\, University of Liverpool (UK)  \nModerator: Vincent H. Tam\, Professor\, University of Houston (US)  \nIn this webinar\, Shampa Das will give an overview of her work in studying the PK/PD and probability of target attainment for dose selection. \nTopics discussed will include: \n\nAn overview of what is meant by the probability of target attainment (PTA)\nHow it is calculated and what data is used for this\nHow PTA is used for decision making during drug development\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 12 May 2020\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-probability-of-target-attainment-analyses-for-dose-selection-in-antimicrobial-drug-development/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200428T110000
DTEND;TZID=America/New_York:20200428T123000
DTSTAMP:20260403T183359
CREATED:20200330T142019Z
LAST-MODIFIED:20200422T140647Z
UID:3937-1588071600-1588077000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Inhaled antimicrobials: Do we get the drug to the bug?
DESCRIPTION:Speaker: Harm A. W. M. Tiddens\, Professor of Pediatric Pulmonology and Allergology\, Erasmus Medical Center Sophia Children’s Hospital (Netherlands) \nModerator: Harpal Singh Dhillon\, Global Medical Value Director & Founder\, AntiBx (UK)\n \nIn this webinar\, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this can impact upon the deposition pattern and efficacy of inhaled antibiotics. He will further present the learnings of his research group’s computational fluid dynamic modelling studies and explain why the expectation that inhaled antibiotics result in high concentrations in the lung is unfortunately a misconception. \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 28 April\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-inhaled-antimicrobials-do-we-get-the-drug-to-the-bug/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200320T090000
DTEND;TZID=America/New_York:20200320T170000
DTSTAMP:20260403T183359
CREATED:20200214T151818Z
LAST-MODIFIED:20200214T151818Z
UID:3792-1584694800-1584723600@carb-x.org
SUMMARY:BAARN2020: Boston Area Antimicrobial Research Network Meeting
DESCRIPTION:The Boston Area Antimicrobial Resistance Network Meeting\, to be held on Friday\, March 20th. \n\nBAARN2020 will be the 7th iteration of this flagship MSI event\, bringing together our collective talents across academia and industry to address the persistent dilemma posed by antimicrobial resistant infection.\n \nTalks will begin at 9 AM in the Northwest Labs Building at 52 Oxford Street\, Cambridge MA 02138\, and our sessions will conclude with the annual Stuart Levy Lecture. A reception will follow at 6 PM at the Harvard Museum of Natural History next door.
URL:https://carb-x.org/event/baarn2020-boston-area-antimicrobial-research-network-meeting/
LOCATION:Harvard Campus\, 52 Oxford Street\, Cambridge\, MA\, 02138\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200227T110000
DTEND;TZID=America/New_York:20200227T123000
DTSTAMP:20260403T183359
CREATED:20200127T163753Z
LAST-MODIFIED:20200127T163906Z
UID:3761-1582801200-1582806600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - PK/PD murine infection models: Focus on study elements\, variability\, and interpretation of results
DESCRIPTION:In this webinar\, Alexander J. Lepak will review critical study elements that lead to robust preclinical PK/PD results in the murine model. \nTopics discussed will include: \n\nUnderstanding and embracing the inherent variability in many components of the murine model\nDemonstrating how to generate and interpret preclinical murine model PK/PD results\n\nThe presentation will be followed by a Q&A session. \nThe material presented in this webinar was shown but not recorded at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019. \nSpeaker: Alexander J. Lepak\, Assistant Professor\, Department of Medicine\, University of Wisconsin School of Medicine and Public Health (USA) \nModerator: Peter Warn\, Evotec (UK) \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-pk-pd-murine-infection-models-focus-on-study-elements-variability-and-interpretation-of-results/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T110000
DTEND;TZID=America/New_York:20200204T123000
DTSTAMP:20260403T183359
CREATED:20200127T162038Z
LAST-MODIFIED:20200127T162038Z
UID:3752-1580814000-1580819400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Non-traditional antibacterial therapeutic options and challenges
DESCRIPTION:In this webinar\, the following aspects will be presented: \n\nDiscovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline\nThese approaches include anti-virulence strategies\, microbiome-modifying therapies\, phages and others such as nanoparticles\, immunotherapy and drug-resistance modulation\nSome of these approaches require novel preclinical efficacy models to predict clinical outcome\nPathogen-specific or even patient-specific strategies dominate this field\nA major challenge will be to show efficacy in clinical trials\n\nThe presentation will be followed by a Q&A session with Ursula Theuretzbacher and Laura Piddock (GARDP). \nSpeaker: Ursula Theuretzbacher\, CEFAIA\, Austria \nModerator: Prabhavathi Fernandes\, Chair of GARDP’s Scientific Advisory Committee \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-non-traditional-antibacterial-therapeutic-options-and-challenges/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T110000
DTEND;TZID=America/New_York:20200121T123000
DTSTAMP:20260403T183359
CREATED:20200127T162345Z
LAST-MODIFIED:20200127T162345Z
UID:3755-1579604400-1579609800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Testing for the potential of emergence of antimicrobial resistance
DESCRIPTION:In this webinar\, the following aspects will be presented: \n\nWhat are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?\nWhat are some techniques that may be used to understand the origins of resistance selection?\nHow to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?\n\nThe presentation will be followed by a Q&A session. \nThis presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’\, jointly organized by GARDP\, CARB-X\, REPAIR Impact Fund\, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019.  \n  \nSpeaker: Michael Mourez\, Head BacteriOmics Platform\, Evotec (France) \nModerator: Laura Piddock\, Director Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-testing-for-the-potential-of-emergence-of-antimicrobial-resistance/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T080000
DTEND;TZID=America/New_York:20200121T170000
DTSTAMP:20260403T183359
CREATED:20200127T163257Z
LAST-MODIFIED:20200127T163257Z
UID:3757-1579593600-1579626000@carb-x.org
SUMMARY:Davos 2020 World Economic Forum - Novo Nordisk Foundation and Novo Holdings: The Broken Model of Antimicrobial resistance
DESCRIPTION:Moderator: Kevin Outterson\, Executive Director\, CARB-X\, Professor of Law\, Boston University \nPanel: \n\nLars Rebien Sorensen\, Chairman of the Novo Nordisk Foundation and Novo Holdings\nJeremy Farrar\, Director\, Wellcome Trust\nDr. Malin Grape\, Head of Antibiotics Unit\, The Public Health Agency of Sweden\nThomas Cueni\, Director General\, IFPMA\nJayasree K. Iyer\, Executive Director\, Access to Medicine Foundation\nFrancesca Colombo\, Head of the Health Division\, OECD\n\nAntimicrobial resistance is one of the biggest threats to human health. The Novo Nordisk Foundation is hosting a session at the World Economic Forum’s Annual Meeting in Davos urging governments\, the biopharma industry and other stakeholders to step up the urgency and respond to the crisis in #antimicrobialresistance with new funding models.  \nTo watch a recording of this panel\, please click here. 
URL:https://carb-x.org/event/davos-2020-world-economic-forum-novo-nordisk-foundation-and-novo-holdings-the-broken-model-of-antimicrobial-resistance/
LOCATION:DAVOS-KLOSTERS\, Switzerland
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200116T103000
DTEND;TZID=America/New_York:20200116T163000
DTSTAMP:20260403T183359
CREATED:20191206T175155Z
LAST-MODIFIED:20191206T175155Z
UID:3653-1579170600-1579192200@carb-x.org
SUMMARY:Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives
DESCRIPTION:Speakers include Kevin Outterson\, Executive Director of CARB-X. \nThe rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities\, in part due to payment decisions that don’t reflect the value of antibiotics that extends beyond the hospital stay. For years\, policy makers and other stakeholders have been exploring ways to improve the antibiotic ecosystem through development\, regulatory\, and market incentives proposals\, though to date there has been limited impact on manufacturers’ ability to generate adequate ROI. \nThis public meeting will highlight recent actions implemented by stakeholders in the U.S. and globally\, and present additional opportunities to effect change to payment and the costs and returns to antimicrobial investment systems through legislative\, administrative\, and private sector mechanisms.
URL:https://carb-x.org/event/exploring-opportunities-to-reform-antimicrobial-payment-and-post-market-incentives/
LOCATION:Washington Marriott at Metro Center\, 775 12th Street NW\, Washington\, DC\, 20005\, United States
END:VEVENT
END:VCALENDAR